SER Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SER is not a good buy right now for an impatient investor. The stock is digesting a big FDA-IND catalyst pop and is already pulling back (-6.78% regular session, -3.95% pre-market) with no supportive proprietary buy signals today. While momentum indicators are mildly constructive, near-term pattern-based odds skew slightly negative over the next week and fundamentals remain pre-revenue with widening losses—so the risk/reward is not attractive for an immediate entry.
Price/Trend: After a sharp catalyst-driven spike (shares recently surged ~35% on IND news), the stock is now retracing with a meaningful red day, suggesting post-news profit-taking rather than clean trend continuation.
Momentum: MACD histogram is positive and expanding (0.107), which supports bullish momentum if price can stabilize above support. RSI(6) ~65.9 is neutral-to-slightly warm (not overbought), but not a strong “oversold bounce” setup either.
Moving averages: Converging moving averages indicate consolidation/indecision—often a setup phase, but direction is not confirmed.
Key levels: Current price 3.22 is just above the pivot/support area (Pivot 3.186). If it loses ~3.19 decisively, next support is around 2.586 (S1). Upside resistance to clear is 3.785 (R1), then 4.156 (R2).
Short-horizon statistical trend: Similar-pattern projection shows ~50% chance of a small decline (next day -0.47%, next week -1.19%), and only flat-to-slightly positive over a month (+0.09%).
Intellectia Proprietary Trading Signals
Latest quarter (2025/Q3): Revenue fell to 0 (-100% YoY), indicating the company is effectively pre-revenue. Net income worsened to -$4.585M (down -425% YoY) and EPS declined to -0.44 (down -438% YoY). This shows accelerating losses rather than improving operating leverage, which makes the stock more dependent on clinical/news catalysts than fundamental growth right now.
No analyst rating/price target change data was provided, implying limited or no recent Wall Street coverage updates. Pros (typical bull view): IND clearance de-risks the ability to start/advance the program and can expand optionality. Cons (typical bear view): no revenue and widening losses mean dilution/financing risk and valuation is mainly sentiment-driven until clinical data arrives.
Influential/congress activity: No recent congress trading data available; hedge fund and insider trends are reported as neutral with no significant recent activity.
